BIODEFENSE ANTIVIRALS AND ANTIBIOTICS Release Date: June 13, 2002 NOTICE: NOT-AI-02-029 National Institute of Allergy and Infectious Diseases (NIAID) (http://www.niaid.nih.gov) Receipt Date for Letter of Interest: July 12, 2002 The National Institute of Allergy and Infectious Diseases (NIAID) wishes to expedite development of two classes of currently licensed and marketed drugs for treatment of potential agents of bioterrorism: (1) Antiviral drugs for treatment of viral hemorrhagic fevers, and (2) Antibiotics for treatment of anthrax, pneumonic plague, and tularemia. NIAID is interested in receiving letters of interest regarding screening, development, and future licensure from organizations that have candidate drugs and the needed research capabilities. Interested organizations should submit a letter of interest that contains a detailed description of their potential development plans, and their R&D capabilities and interest. The letter of interest along with any supporting documentation shall not exceed 10 pages. Letters of interest will be kept confidential and will help in determining the need for an RFP to support further development, testing, and licensure of these products, and in assembling a potential source list for distribution if an RFP is issued. INQUIRIES Submit your response to the address listed below: Barbara A. Shadrick Senior Contracting Officer Contract Management Branch, DEA National Institute of Allergy and Infectious Diseases, NIH 6700-B Rockledge Drive, Room 2230, MSC 7612 Bethesda, MD 20892-7612 Phone: 301-496-7288 Fax: 301-480-5253 or 301-402-0972 E-Mail: bs92y@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |